No Data
No Data
Austar Lifesciences Limited (HKG:6118) Stock Catapults 50% Though Its Price And Business Still Lag The Industry
The "DeepSeek Moment" of medicine, has China’s Innovative Drugs also reached it?
Over the past four years, China's share of Global large-scale pharmaceutical Trade has surged from 5% to 30%. From research and development innovation to international mergers and acquisitions, Chinese Innovative Drugs companies are reshaping the Global pharmaceutical innovation landscape.
Austar Lifesciences Expects to Turn to Profit in 2024
AUSTAR (06118.HK) profit alert: Annual net profit is expected to be between 15 million and 20 million yuan.
Gelonghui, January 27th丨AUSTAR (06118.HK) announced that it expects to record a profit attributable to the company's owners of approximately 15 million to 20 million yuan for the financial year ending December 31, 2024, while it expects a loss attributable to the company's owners of approximately 0.113 billion yuan for the financial year ending December 31, 2023. The expected turnaround from loss to profit is mainly attributed to: (1) no losses recorded from the company's then indirect non-wholly owned subsidiaries H+E Pharma GmbH and S-Tec GmbH for the financial year ending December 31, 2023.
Express News | Austar Lifesciences - Expected Result Due to Absence of a Loss of RMB116.5 Mln, Others
Express News | Austar Lifesciences Sees Profit Attributable for FY RMB 15 Mln to RMB 20 Mln